Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny, Inc. is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package. Through an in-house network of fertility specialists and clinics, Progyny provides members with access to pre-negotiated pricing, personalized treatment pathways and dedicated care advocates. Complementing these services is a suite of digital resources, including appointment scheduling tools, educational content and real-time treatment tracking, designed to simplify care coordination and reduce administrative burdens.

Founded in 2016, Progyny filed for its initial public offering in October 2019 and began trading on the NASDAQ under the ticker PGNY. The company was established by Michael J. Schulman, who serves as chief executive officer and has guided its growth from a startup to a publicly traded business. Under his leadership, Progyny has expanded its team of clinical advisors and invested in technology to enhance patient engagement and clinical decision support.

Progyny’s services are currently available throughout the United States, with corporate clients spanning technology, finance, manufacturing and other sectors. Headquartered in New York City, the company maintains additional offices in major U.S. markets and collaborates with employers nationwide to provide scalable, outcomes-driven fertility solutions. By combining clinical best practices with data-driven insights, Progyny seeks to set new standards in reproductive healthcare benefits.

Key Stats

• Today's Range: $19.27 to $19.66
• 50-Day Range: $19.17 to $23.78
• 52-Week Range: $13.39 to $26.76
• Volume: 286,031 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $1.67 billion
• P/E Ratio: 33.00
• Dividend Yield: N/A
• Price Target: $25.44
• Consensus Rating: Moderate Buy

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 70% of companies evaluated by MarketBeat, and ranked 302nd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Progyny has a consensus price target of $25.44, representing about 30.9% upside from its current price of $19.44.

Amount of Analyst Coverage

Progyny has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 8.33%

Earnings Growth

Earnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 32.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 82.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 32.92, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.78.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.81% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Progyny has recently increased by 2.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.81% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in Progyny has recently increased by 2.47%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.45

News Sentiment

Progyny has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Progyny this week, compared to 8 articles on an average week.

Search Interest

6 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Progyny to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $179,311.00 in company stock.

Percentage Held by Insiders

Only 9.40% of the stock of Progyny is held by insiders.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PGNY Stock Analysis - Frequently Asked Questions

How have PGNY shares performed this year?

Progyny's stock was trading at $17.25 at the start of the year. Since then, PGNY shares have increased by 12.7% and is now trading at $19.44.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) announced its earnings results on Thursday, August, 7th. The company reported $0.19 EPS for the quarter, missing analysts' consensus estimates of $0.42 by $0.23. Progyny's quarterly revenue was up 9.5% on a year-over-year basis.
Read the conference call transcript.

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's top institutional investors include Fort Washington Investment Advisors Inc. OH (1.93%), Pacer Advisors Inc. (0.45%), Voya Investment Management LLC (0.28%) and State of Alaska Department of Revenue (0.05%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Allison Swartz, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/24/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 310
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Progyny: $25.44
• High Price Target: $28.00
• Low Price Target: $17.00
• Potential Upside/Downside: +30.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.59
• Trailing P/E Ratio: 32.92
• Forward P/E Ratio: 32.40
• P/E Growth: 1.63
• Net Income: $54.34 million
• Net Margins: 4.28%
• Pretax Margin: 7.18%
• Return on Equity: 10.69%
• Return on Assets: 7.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.70
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $1.17 billion
• Price / Sales: 1.43
• Cash Flow: $0.35 per share
• Price / Cash Flow: 55.55
• Book Value: $4.96 per share
• Price / Book: 3.92

Miscellaneous

• Outstanding Shares: 85,980,000
• Free Float: 77,900,000
• Market Cap: $1.67 billion
• Optionable: Optionable
• Beta: 1.34